This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth. Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 49. Updates on Low-Risk MDS with Dr. Maximilian Stahl
43:23
43:23
Afspil senere
Afspil senere
Lister
Like
Liked
43:23
In this episode, we discuss updates on low-risk MDS with Dr. Maximilian Stahl with a focus on imetelstat and luspatercept. Here are the trials we discussed: 1. IWG 2019 response criteria https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042664/ 2. MEDALIST trial: Luspatercept https://www.nejm.org/doi/10.1056/NEJMoa1908892?url_ver=Z39.88-2003&rfr_id=ori…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 48. Management of Polycythemia Vera with Dr. Aaron Gerds
57:09
57:09
Afspil senere
Afspil senere
Lister
Like
Liked
57:09
In this episode, we discussed the diagnosis and management of polycythemia vera with Dr. Aaron T. Gerds. Here are the shownotes with the key studies discussed: 1. MIPS PV scoring system https://pubmed.ncbi.nlm.nih.gov/31945802/ 2. REVEAL study https://ashpublications.org/blood/article/143/16/1646/506717/Association-between-elevated-white-blood-cell…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 47. ASCO/EHA 2024 Lymphoma Updates with Dr. Gloria Iacoboni
47:48
47:48
Afspil senere
Afspil senere
Lister
Like
Liked
47:48
In this episode, we reviewed the hottest updates in lymphoma from ASCO and EHA 2024, held in Chicago and Madrid respectively, with Dr. Gloria Iacoboni, a haematologist from University Hospital Vall d'Hebron, in Barcelona, Spain. Here are the key abstracts we discussed: 1. STARGLO: Glofit-GEMOX vs R-GEMOX in relapsed/refractory DLBCL https://library…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 46. Updates in Myeloma MRD with Dr. Ben Derman and Dr. Manni Mohyuddin
57:48
57:48
Afspil senere
Afspil senere
Lister
Like
Liked
57:48
In this episode, we dive into updates in Minimal Residual Disease (MRD) in multiple myeloma, along with the FDA ODAC meeting in April 2024 to decide on MRD as a surrogate endpoint for accelerated approval. Our guests are Dr. Benjamin Derman and Dr. Manni Mohyuddin. Here are the key papers we discussed: 1. Recording of FDA ODAC meeting: https://www.…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 45. Updates in Primary Myelofibrosis with Dr. Ayalew Tefferi
1:00:53
1:00:53
Afspil senere
Afspil senere
Lister
Like
Liked
1:00:53
In this episode, we discuss updates in primary myelofibrosis with Dr. Ayalew Tefferi from the Mayo Clinic. The key studies and trials discussed are as follows: · GIPSS: Genetically inspired prognostic scoring system that is exclusively based on genetic markers. § https://www.nature.com/articles/s41375-018-0107-z · MIPSS70+ Version 2.0: Mutation and…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 44. Maintenance Therapy in Multiple Myeloma with Dr. Hira Mian and Dr. Manni Mohyuddin
52:58
52:58
Afspil senere
Afspil senere
Lister
Like
Liked
52:58
In this episode, we dive into the data on maintenance therapy in multiple myeloma with Dr. Hira Mian and Dr. Manni Mohyuddin. Here are the key studies we discussed: 1. Meta-analysis of individual patient-level data from CALGB, IFM, and Italian maintenance RCTs (lenalidomide vs placebo or observation): https://pubmed.ncbi.nlm.nih.gov/28742454/ 2. My…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 43. Essential Thrombocythemia with Dr. Raajit Rampal
35:28
35:28
Afspil senere
Afspil senere
Lister
Like
Liked
35:28
In this episode, we discuss the diagnosis and management of Essential Thrombocythemia with Dr. Raajit Rampal. Here are the shownotes: 1. IPSET (revised) system, risk categories are defined by the presence of a prior thrombosis, age, and JAK2 mutation status: · Very low risk: No prior thrombosis, age ≤60 years, JAK2-unmutated · Low risk: No prior th…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 42. CAR T-cell Therapy in Early Relapsed Myeloma with Dr. Samer Al Hadidi
54:49
54:49
Afspil senere
Afspil senere
Lister
Like
Liked
54:49
In this episode, we talked about overall survival data from CARTITUDE-4 and KarMMa-3 that was presented at FDA ODAC meeting with Dr. Samer Al Hadidi from University of Arkansas Myeloma Center. RCTs of BCMA CAR T-cell Therapy in Early Relapsed Multiple Myeloma: a) KarMMa-3 (ide-cel): https://pubmed.ncbi.nlm.nih.gov/36762851/ b) CARTITUDE-4 (cilta-ce…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 41. Career Development as a Clinician-Investigator with Dr. Ayalew Tefferi
47:22
47:22
Afspil senere
Afspil senere
Lister
Like
Liked
47:22
In this episode, we discuss mentorship and career development as a clinician-investigator with Dr. Ayalew Tefferi from the Mayo Clinic.Af Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 40. Management of Newly Diagnosed AL Amyloidosis with Dr. Angela Dispenzieri
52:34
52:34
Afspil senere
Afspil senere
Lister
Like
Liked
52:34
In this episode we discuss the management of newly diagnosed AL amyloidosis with Dr. Angela Dispenzieri from the Mayo Clinic. Here are the key articles discussed: 1. Optimal use of tissue biopsy in AL amyloidosis: https://pubmed.ncbi.nlm.nih.gov/28271734/ 2. Mayo 2004 staging: https://pubmed.ncbi.nlm.nih.gov/15365071/ 3. Mayo 2012 staging: https://…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 39. ASH 2023 Leukemia and Myeloid Neoplasm Recap with Dr. Anand Patel
55:14
55:14
Afspil senere
Afspil senere
Lister
Like
Liked
55:14
In this episode, we discuss top abstracts in the myeloid space from the American Society of Hematology 2023 meeting with Dr. Anand Patel. Here are the abstracts that were discussed: 1. TRANSFORM-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitini…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 38. GVHD Prophylaxis in Allo-Transplant with Dr. Shernan Holtan
52:10
52:10
Afspil senere
Afspil senere
Lister
Like
Liked
52:10
In this episode, we talk about GVHD prophylaxis, including recent data on post-transplant cyclophosphamide and abatacept with Dr. Shernan Holtan from the University of Minnesota. Here are the key trials we discussed: 1. BMT CTN 1203 trial: Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate,…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 37. ASH 2023 Myeloma Recap with Dr. Ben Derman
1:01:40
1:01:40
Afspil senere
Afspil senere
Lister
Like
Liked
1:01:40
In this episode, we discuss the key abstracts in myeloma and related plasma cell disorders at ASH23 with Dr. Benjamin Derman. Here are the abstracts discussed in this episode: First, we will focus on a few abstracts in precursor states, MGUS. 1. New diagnostic criteria for light chain MGUS (IStopMM): https://ash.confex.com/ash/2023/webprogram/Paper…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 36. ASH 2023 Lymphoma Recap with Dr. Toby Eyre
50:59
50:59
Afspil senere
Afspil senere
Lister
Like
Liked
50:59
In this episode, we review the hottest updates in lymphoma from the American Society of Hematology 2023 meeting with Dr Toby Eyre, a consultant haematologist at the University of Oxford in the UK. Here are the abstracts that were discussed: Mantle Cell Lymphoma 1. BOVen trial-A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 35. Bispecific Antibodies in Lymphoma with Dr. Michael Dickinson
1:08:40
1:08:40
Afspil senere
Afspil senere
Lister
Like
Liked
1:08:40
In this episode, we delve into the weeds of bispecific antibodies across lymphomas with Dr. Michael Dickinson from Peter MacCallum Cancer Center, Melbourne, Australia. Here are the key articles we discussed: 1. Glofitamab for Relapsed/Refractory DLBCL: https://pubmed.ncbi.nlm.nih.gov/36507690/ 2. Long-term follow-up data on blinatumomab in relapsed…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 34. Management of FLT3 AML with Dr. Alexander Perl
1:08:19
1:08:19
Afspil senere
Afspil senere
Lister
Like
Liked
1:08:19
In this episode, we dive into the management of newly diagnosed and relapsed FLT3-positive AML with Dr. Alexander Perl. Here are the shownotes: 1. Assessment of minimal residual disease in standard-risk AML https://www.nejm.org/doi/full/10.1056/nejmoa1507471 2. RATIFY study: Midostaurin plus chemotherapy for AML with a FLT3 mutation https://www.nej…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 33. The art of caring for patients at the end of life with Dr. Azra Raza
59:15
59:15
Afspil senere
Afspil senere
Lister
Like
Liked
59:15
In this episode, we discuss the art of caring for terminally ill patients with Dr. Azra Raza. We also discuss her book titled "The First Cell", where she recounts numerous poignant stories of her patients with terminal cancer, and teaches us how to find hope amidst despair. Link to the book: https://www.amazon.com/First-Cell-Human-Pursuing-Cancer/d…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 32: t(11;14) Multiple Myeloma and Role of Venetoclax with Dr. Rafael Fonseca and Dr. Martin Kaiser
58:50
58:50
Afspil senere
Afspil senere
Lister
Like
Liked
58:50
In this episode, we discuss the biology and management of t(11;14) multiple myeloma and the role of venetoclax with Dr. Rafael Fonseca and Dr. Martin Kaiser. Here are the shownotes: 1. Excellent tweetorial thread by Dr. Fonseca highlighting some of the historical studies that identified t(11;14) and its prognostic impact in myeloma: https://x.com/R…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 31. Management of CNS Lymphoma
51:40
51:40
Afspil senere
Afspil senere
Lister
Like
Liked
51:40
In this episode, we discuss the management of primary CNS lymphoma, secondary CNS lymphoma and CNS prophylaxis with Dr. Kate Cwynarski. Here are the shownotes: 1. ASH 2022 data on PET scan in CNS lymphoma - https://ashpublications.org/blood/article/140/Supplement%201/1334/492207/Is-It-Possible-to-Omit-Bone-Marrow-Biopsy-in?searchresult=1 2. Elizabe…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 30. Management of High-Risk Myeloma
1:08:29
1:08:29
Afspil senere
Afspil senere
Lister
Like
Liked
1:08:29
In this episode, we discuss with Dr. Martin Kaiser how to identify and manage newly diagnosed high-risk multiple myeloma in the current era of effective frontline therapies. Here are the key studies that we touched upon: 1. Phase II OPTIMUM (MUKnine) trial in ultra-high-risk myeloma and PCL: https://pubmed.ncbi.nlm.nih.gov/37315268/ 2. Meta-analysi…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 29. Management of Peripheral T-Cell Lymphoma
56:13
56:13
Afspil senere
Afspil senere
Lister
Like
Liked
56:13
In this episode, we discuss the diagnosis and management of peripheral T-cell lymphoma with Dr. Steven Horwitz, with a focus on the 3 most common types-Peripheral T-cell Lymphoma-NOS, Angioimmunoblastic T-cell Lymphoma (AITL), and Anaplastic Large Cell Lymphoma (ALCL). Here are the key papers we discussed: 1. “How I Treat Peripheral T-cell Lymphoma…
…
continue reading
In this episode, we discuss the diagnosis and management/monitoring of Clonal Cytopenias of Unknown Significance (CCUS) with Dr. Uma Borate. We also discuss the emerging data on risk stratification and key trials in this space that are currently ongoing. Here are the shownotes: 1. CCUS and risk of transformation to myeloid neoplasms: https://www.sc…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 27. Management of PNH
1:03:29
1:03:29
Afspil senere
Afspil senere
Lister
Like
Liked
1:03:29
In this episode, we delve into the diagnosis and management of Paroxysmal Nocturnal Hemoglobinuria (PNH) with Dr. Robert Brodsky. Here are the shownotes for key papers we discussed in the episode: How I treat PNH: https://pubmed.ncbi.nlm.nih.gov/33512400/ Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired sev…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 26. Management of Newly Diagnosed Hodgkin's Lymphoma
57:26
57:26
Afspil senere
Afspil senere
Lister
Like
Liked
57:26
In this episode, we delve into the history of frontline treatment in young/fit patients with Hodgkin's lymphoma and recent developments in the past decade with Dr. Nancy Bartlett from Washington University. Link for our Blood Cancer Talks Survey: https://bit.ly/BCTS Here are the key trials we discussed: 1. RATHL Trial (PET-adapted treatment of Adva…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 25. Managing Acute Toxicities of CAR T-cell Therapy
49:08
49:08
Afspil senere
Afspil senere
Lister
Like
Liked
49:08
In this episode, we discuss the management of acute toxicities of CAR T-cell therapy, including CRS, ICANS, and HLH with Dr. Michael Jain from Moffitt Cancer Center. Here are some of the key articles we discussed: 1. “How I treat refractory CRS and ICANS after CAR T-cell therapy”. https://pubmed.ncbi.nlm.nih.gov/36989488/ 2. CAR-HEMATOTOX score: ht…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 24. ASCO/EHA 2023 Special: Updates on CAR T-cell Therapy in Myeloma
47:30
47:30
Afspil senere
Afspil senere
Lister
Like
Liked
47:30
In this episode, we discuss the latest updates on CAR T-cell therapy in multiple myeloma, including the studies presented at ASCO and EHA 2023. Here are the show notes: 1. For a primer on CAR T-cell therapy, listen to our episode aired on July 22nd 2022 with Dr. Surbhi Sidana: https://share.transistor.fm/s/efc4acf9 2. RCTs of BCMA CAR T-cell Therap…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 23. Bispecific Antibodies in Myeloma
51:35
51:35
Afspil senere
Afspil senere
Lister
Like
Liked
51:35
In this episode, we delve into the latest data on bispecific antibodies in multiple myeloma with Dr. Ajai Chari. Here are the key studies discussed: 1. Teclistamab (MajesTEC-1 trial): https://pubmed.ncbi.nlm.nih.gov/35661166/ 2. Correlative analysis from MajesTEC-1 trial: https://ashpublications.org/blood/article/140/Supplement%201/241/487619 3. Ta…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 22. Management of Low-Risk MDS
1:03:46
1:03:46
Afspil senere
Afspil senere
Lister
Like
Liked
1:03:46
In this episode, we take a deep dive into low-risk MDS management. We have the privilege of being joined by the esteemed Dr. Mikkael Sekeres. We also explore his invaluable insights gained from his time at FDA ODAC and his latest literary endeavor, "Drugs and the FDA". Here are the key studies discussed: 1. ASH choosing wisely: https://www.hematolo…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 21. Newly Diagnosed Mantle Cell Lymphoma
46:05
46:05
Afspil senere
Afspil senere
Lister
Like
Liked
46:05
In this episode, we delve into the management of newly diagnosed mantle cell lymphoma with Dr. Martin Dreyling. Here the shownotes: 2:11 How to diagnose mantle cell lymphoma (MCL)? 6:51 Clinical manifestations of mantle cell lymphoma 7:52 How to manage leukemic variant of MCL? 12:08 Is Watch-and-Wait reasonable in selected cases of nodal MCL with l…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 20. Management of Myeloma in LMICs
57:25
57:25
Afspil senere
Afspil senere
Lister
Like
Liked
57:25
In this episode, we discuss the management of multiple myeloma in LMICs with Dr. Andrés Gómez-De León from UANL, Monterrey, Mexico, and Dr. Aditya Jandial from PGIMER, Chandigarh, India. This episode was inspired by an article in Lancet Haematology titled “The Underrepresented Majority”, which highlighted the lack of access to some of the basic ant…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 19. Management of Primary Myelofibrosis
59:16
59:16
Afspil senere
Afspil senere
Lister
Like
Liked
59:16
In this episode, we discuss the diagnosis and management of primary myelofibrosis with Dr. Ayalew Tefferi at Mayo Clinic, Rochester, Minnesota. Here are the show notes, including key studies discussed in this episode: 1. Risk stratification of PMF: MIPSS70 Score: http://www.mipss70score.it https://ascopubs.org/doi/full/10.1200/JCO.2017.76.4886 Gene…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 18. Management of Smoldering Multiple Myeloma
46:32
46:32
Afspil senere
Afspil senere
Lister
Like
Liked
46:32
1. How I Approach Smoldering Myeloma (Vaxman and Gertz): https://ashpublications.org/blood/article/140/8/828/485274 2. Risk-Stratification Models in SMM: Mayo 2018 model: https://pubmed.ncbi.nlm.nih.gov/29895887/ PETHEMA (Spanish) model: https://pubmed.ncbi.nlm.nih.gov/17576818/ PANGEA model: https://pubmed.ncbi.nlm.nih.gov/36858677/ IMWG SMM model…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 17. Acquired Aplastic Anemia
46:29
46:29
Afspil senere
Afspil senere
Lister
Like
Liked
46:29
In this episode, we discuss the management of acquired aplastic anemia with Dr. Amy DeZern. Here are the links to some of the key articles discussed in this show: 1. Review article on aplastic anemia: https://www.nejm.org/doi/10.1056/NEJMra1413485 2. RCTs testing whether addition of cyclosporine to ATG improves outcomes in aplastic anemia: https://…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 16. ASH 2022 Leukemia and Myeloid Malignancies Recap
55:12
55:12
Afspil senere
Afspil senere
Lister
Like
Liked
55:12
1. Phase III ASAP trial https://ash.confex.com/ash/2022/webprogram/Paper159962.html 2. Phase III Dauno-Double Trial https://ash.confex.com/ash/2022/webprogram/Paper157126.html 3. Reduced venetoclax exposure: https://ash.confex.com/ash/2022/webprogram/Paper165464.html 4. Menin Inhibitors in AML https://ash.confex.com/ash/2022/webprogram/Paper164849.…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 15. Management of Newly Diagnosed DLBCL (Including Bonus ASH22 Updates)
53:44
53:44
Afspil senere
Afspil senere
Lister
Like
Liked
53:44
In this episode, we discuss the management of newly diagnosed DLBCL with Dr. Pallawi Torka. We also have a few bonus ASH22 updates on DLBCL. Links to articles and abstracts discussed in the episode are as follows: 1. A comprehensive review article on DLBCL: https://pubmed.ncbi.nlm.nih.gov/33657296/ 2. RCT testing CHOP vs Three Intensive Regimens in…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 14. MRD in Multiple Myeloma
53:55
53:55
Afspil senere
Afspil senere
Lister
Like
Liked
53:55
1. Excellent paper on harmonization of performing and reporting MRD in multiple myeloma: https://www.nature.com/articles/s41375-020-01012-4 2. Does CR really matter in the era of MRD? Landmark paper from the Spanish Group: https://pubmed.ncbi.nlm.nih.gov/35560160/ 3. Meta-analysis showing individual-level prognostic impact of MRD on long-term outco…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 13. Management of Newly Diagnosed Younger Adults with AML
49:06
49:06
Afspil senere
Afspil senere
Lister
Like
Liked
49:06
Study showing the time from diagnosis of AML to the start of intensive treatment indicate that a treatment delay has no negative prognostic impact. https://ashpublications.org/blood/article/136/7/823/460669/Does-time-from-diagnosis-to-treatment-affect-the RATIFY clinical trial showing the addition of midostaurin (FLT3 inhibitor) to 7+3 chemotherapy…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 12. ASH 2022 Myeloma Recap
1:02:43
1:02:43
Afspil senere
Afspil senere
Lister
Like
Liked
1:02:43
1. GEM-CESAR and ASCENT Trials: Intensive Treatment Strategy in High-Risk Smoldering Multiple Myeloma https://ash.confex.com/ash/2022/webprogram/Paper159606.html https://ash.confex.com/ash/2022/webprogram/Paper168930.html 2. What are the odds of having BMPC≥10% in a person with MGUS? IstopMM answers this question by developing a prediction model. h…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 11. ASH22 Recap: Lymphoma and CLL
39:02
39:02
Afspil senere
Afspil senere
Lister
Like
Liked
39:02
ALPINE Trial: Zanubrutinib vs Ibrutinib in Relapsed/Refractory CLL (https://www.nejm.org/doi/full/10.1056/NEJMoa2211582) CLL2-Give Trial: Updated results Obinutuzumab (G), Ibrutinib (I), and Venetoclax (Ve) triplet in Untreated Patients with CLL with 17p Deletion/TP53 Mutation (https://ash.confex.com/ash/2022/webprogram/Paper163245.html) AVO Trial:…
…
continue reading
Excellent overview of Castleman Disease: https://ashpublications.org/blood/article/135/16/1353/452573/Overview-of-Castleman-disease International consensus guideline for treatment of Idiopathic Multicentric Castleman Disease (iMCD): https://ashpublications.org/blood/article/132/20/2115/39506/International-evidence-based-consensus-treatment Somatic …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 9. CAR-T cell therapy in Lymphoma
51:17
51:17
Afspil senere
Afspil senere
Lister
Like
Liked
51:17
In this episode, we discussed the three CD19-directed chimeric antigen receptor (CAR T-cell) therapies that have been approved for relapsed/refractory aggressive large B cell lymphomas (LBCL) after two lines of therapy: Axicabtagene ciloleucel (axi-cel) https://www.nejm.org/doi/full/10.1056/nejmoa1707447 Tisagenlecleucel (tisa-cel) https://www.nejm…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 8. Management of Newly Diagnosed CLL
1:02:40
1:02:40
Afspil senere
Afspil senere
Lister
Like
Liked
1:02:40
Key articles and trials discussed in the episode: 1. Excellent review in NEJM on treatment of CLL (2020): https://www.nejm.org/doi/full/10.1056/NEJMra1908213 2. Alliance Trial (Ibrutinib vs chemoimmunotherapy in older patients with untreated CLL): https://www.nejm.org/doi/full/10.1056/NEJMoa1812836 3. E1912 (Ibrutinib vs chemoimmunotherapy in young…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 7. Newly Diagnosed Ph-negative ALL
48:05
48:05
Afspil senere
Afspil senere
Lister
Like
Liked
48:05
Key papers discussed in the show: 1. Pediatric regimen for older adolescents and young adults with ALL: CALGB 10403 https://ashpublications.org/blood/article/133/14/1548/260519/A-pediatric-regimen-for-older-adolescents-and 2. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: C19802 https://a…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 6. Donor Search for Allogeneic Hematopoietic Stem Cell Transplant
48:16
48:16
Afspil senere
Afspil senere
Lister
Like
Liked
48:16
Key papers discussed in the show: 1. Landmark paper on HLA-mismatch and survival: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4568127/ 2. HLA-DP and Risk of GVHD: https://www.nejm.org/doi/full/10.1056/NEJMoa1500140 3. Outcomes of Allogeneic Transplant with HLA-Mismatched Unrelated Donor: https://ascopubs.org/doi/10.1200/JCO.20.03502 4. Review/pers…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 5. Mentorship and Career Development
40:57
40:57
Afspil senere
Afspil senere
Lister
Like
Liked
40:57
In this episode, we do a thought provoking discussion with Dr. Marty Tallman on mentorship and career development in academic hematology and medical oncology. A must listen for all trainees and early career clinical investigators. Sage wisdom from a legend in the field!Af Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 4. Measurable Residual Disease in AML
1:02:50
1:02:50
Afspil senere
Afspil senere
Lister
Like
Liked
1:02:50
2021 European LeukemiaNET MRD Working Party Consensus Guidelines: https://pubmed.ncbi.nlm.nih.gov/34724563/ Pre-MEASURE Study ASCO 2022: https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.7006Af Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 3. Management of Waldenström Macroglobulinemia
46:11
46:11
Afspil senere
Afspil senere
Lister
Like
Liked
46:11
https://ascopubs.org/doi/abs/10.1200/JCO.22.00495Af Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 2. CAR T-Cell Therapy in Multiple Myeloma
31:32
31:32
Afspil senere
Afspil senere
Lister
Like
Liked
31:32
In this episode, we discuss with Dr. Surbhi Sidana the latest advances, practical aspects of patient management, and future directions of cellular therapies in multiple myeloma.Af Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 1. Implications of Clonal Hematopoiesis
50:50
50:50
Afspil senere
Afspil senere
Lister
Like
Liked
50:50
In this episode, we bring two experts in clonal hematopoiesis, Dr. Sid Jaiswal from Stanford University and Dr. Alex Bick from Vanderbilt University to dissect the biology, potential clinical implications, and future of clonal hematopoiesis.Af Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
…
continue reading
BloodCancerTalks is a new podcast focusing exclusively on hematologic malignancies. We will bring a wide range of experts to dig deep into specific topics and critically appraise the literature. Raj Chakraborty is a hematologist/oncologist and an Assistant Professor of Medicine at Columbia University. Ash Kishtagari is a hematologist/oncologist and…
…
continue reading